SEC Filing Summary: ChromaDex Corporation (CDXC)
Business Context and Reporting Period
This Form 8-K Current Report, dated February 20, 2021, details a material definitive agreement entered into by ChromaDex Corporation. The filing reports on a private placement financing transaction executed on February 20, 2021, with an expected closing date of February 23, 2021.
Key Financial Metrics and Transaction Details
- Financing Amount: $25.0 million aggregate purchase price.
- Security Issued: Common Stock, par value $0.001 per share.
- Purchase Price: $6.50 per share.
- Shares Issued: Approximately 3,846,154 shares (calculated as $25.0 million / $6.50).
- Registration Rights: The Company agreed to file registration statements for the resale of shares. Failure to meet filing or effectiveness deadlines may result in liquidated damages of 1.0% of the aggregate purchase price per month, capped at 5.0%.
- Exemption: The offering relies on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Material Changes and Unusual Items
The primary material change is the entry into a Securities Purchase Agreement and a Registration Rights Agreement. This transaction represents a significant capital raise intended to bolster the Company's liquidity. The filing does not provide comparative financial metrics (revenue, profit, cash flow, or debt levels) for the current or prior periods, as this is a transaction-specific report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the completion, timing, and size of the financing. Management notes that actual results may differ due to risks associated with satisfying customary closing conditions. The Company explicitly states it has no obligation to update these forward-looking statements. Investors are directed to the "Risk Factors" section of the Company's Form 10-Q for the quarter ended September 30, 2020, for a comprehensive list of business risks.
Key Facts for Investor Verification
- Verify the closing of the $25.0 million financing on or around February 23, 2021.
- Confirm the issuance of approximately 3.85 million shares of Common Stock.
- Monitor the Company's compliance with the Registration Rights Agreement to avoid liquidated damages.
- Review the full text of the Securities Purchase Agreement (Exhibit 99.1) and Registration Rights Agreement (Exhibit 99.2) for specific covenants and conditions.
- Check subsequent filings for the impact of this capital raise on the Company's cash position and dilution to existing shareholders.